Repigmentation of Tenacious Vitiligo on Apremilast

Vitiligo is a common pigment disorder characterized by acquired loss of function or absence of melanocytes, leading to distinct areas of depigmentation. Physical exam reveals sharply demarcated, depigmented macules or patches on otherwise normal skin. Vitiligo can present at any age, in any skin col...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara B. Huff, Lorie D. Gottwald
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Dermatological Medicine
Online Access:http://dx.doi.org/10.1155/2017/2386234
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551336742223872
author Sara B. Huff
Lorie D. Gottwald
author_facet Sara B. Huff
Lorie D. Gottwald
author_sort Sara B. Huff
collection DOAJ
description Vitiligo is a common pigment disorder characterized by acquired loss of function or absence of melanocytes, leading to distinct areas of depigmentation. Physical exam reveals sharply demarcated, depigmented macules or patches on otherwise normal skin. Vitiligo can present at any age, in any skin color. There is no specific serologic marker for diagnosis, but patients often have other autoimmune problems. Treatment options are limited and are difficult given the fact that the pathogenesis of the disease is not well elucidated. We present the case of a 52-year-old woman with vitiligo for over 2 decades. The patient’s medical history reveals a lack of response to many different approaches. This case highlights the ability of apremilast, an FDA-approved drug for the treatment of psoriasis and psoriatic arthritis, to achieve repigmentation in a case a vitiligo that has been extremely recalcitrant.
format Article
id doaj-art-cdca0def1dc34f02b8c0145889618a6c
institution Kabale University
issn 2090-6463
2090-6471
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Case Reports in Dermatological Medicine
spelling doaj-art-cdca0def1dc34f02b8c0145889618a6c2025-02-03T06:01:46ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712017-01-01201710.1155/2017/23862342386234Repigmentation of Tenacious Vitiligo on ApremilastSara B. Huff0Lorie D. Gottwald1University of Toledo College of Medicine and Life Sciences, 3000 Arlington Avenue, Toledo, OH 43614, USADepartment of Dermatology, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH 43614, USAVitiligo is a common pigment disorder characterized by acquired loss of function or absence of melanocytes, leading to distinct areas of depigmentation. Physical exam reveals sharply demarcated, depigmented macules or patches on otherwise normal skin. Vitiligo can present at any age, in any skin color. There is no specific serologic marker for diagnosis, but patients often have other autoimmune problems. Treatment options are limited and are difficult given the fact that the pathogenesis of the disease is not well elucidated. We present the case of a 52-year-old woman with vitiligo for over 2 decades. The patient’s medical history reveals a lack of response to many different approaches. This case highlights the ability of apremilast, an FDA-approved drug for the treatment of psoriasis and psoriatic arthritis, to achieve repigmentation in a case a vitiligo that has been extremely recalcitrant.http://dx.doi.org/10.1155/2017/2386234
spellingShingle Sara B. Huff
Lorie D. Gottwald
Repigmentation of Tenacious Vitiligo on Apremilast
Case Reports in Dermatological Medicine
title Repigmentation of Tenacious Vitiligo on Apremilast
title_full Repigmentation of Tenacious Vitiligo on Apremilast
title_fullStr Repigmentation of Tenacious Vitiligo on Apremilast
title_full_unstemmed Repigmentation of Tenacious Vitiligo on Apremilast
title_short Repigmentation of Tenacious Vitiligo on Apremilast
title_sort repigmentation of tenacious vitiligo on apremilast
url http://dx.doi.org/10.1155/2017/2386234
work_keys_str_mv AT sarabhuff repigmentationoftenaciousvitiligoonapremilast
AT loriedgottwald repigmentationoftenaciousvitiligoonapremilast